Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Information Technology

Harpoon Therapeutics

Che-Leung Law

Wendy Chang

Luke Walker

Banmeet Anand

Grace Wang

Alpana Naresh

Meghan Kellam

Haibo Wang

Rick Austin

Annie Winterhall

Bryan Lemon

The executive team at Harpoon Therapeutics has a history of working in the biotechnology industry and studying genetics. The team members have worked at companies such as Amgen, and have degrees from schools such as Texas A&M University and University of California, Davis.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Harpoon Therapeutics

Board of Directors

Leadership Team